Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration.
Edstein
M D
MD
Kotecka
B M
BM
Anderson
K L
KL
Pombo
D J
DJ
Kyle
D E
DE
Rieckmann
K H
KH
Good
M F
MF
D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics / Q000494:pharmacology; D053626:Atovaquone; D001681:Biological Assay; D002851:Chromatography, High Pressure Liquid; D004359:Drug Therapy, Combination; D006207:Half-Life; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy; D009285:Naphthoquinones / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics / Q000494:pharmacology; D010963:Plasmodium falciparum / Q000187:drug effects / Q000235:genetics; D002727:Proguanil / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology
D000962:Antimalarials; D009285:Naphthoquinones; D002727:Proguanil; D053626:Atovaquone